Highlights InnoCan Pharma Corporation Deutsche Boerse AG

Equities

IP4

CA45783P1027

Real-time Estimate Tradegate Other stock markets 11:19:59 2024-07-17 am EDT			5-day change	1st Jan Change
0.164 ^EUR	-0.30%		-0.32%	-19.06%

Jul. 02	Innocan Pharma Engages Pain-Management Expert Ahead of FDA Meeting	MT
Jun. 11	Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Innocan Pharma Engages Pain-Management Expert Ahead of FDA Meeting	Jul. 02	MT
Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs	Jun. 11	MT
InnoCan Pharma Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 27	CI
Innocan Pharma Reports First Quarter 2024 Results With Revenue Growth Of Over 4X To $6.8 Million	May. 27	MT
Refile: FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain	May. 21	MT
InnoCan Pharma Brief: FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain	May. 21	MT
Innocan Pharma Corporation Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey	May. 09	CI
InnoCan Pharma Corporation Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain	Apr. 22	CI
InnoCan Pharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Innocan Pharma Corporation Announces the Signing of an Agreement with the Hebrew University	Mar. 25	CI
InnoCan Pharma "Paves Its Way" to LPT-CBD Chemistry, Manufacturing and Controls (CMC), "Key Milestones" for FDA Approval	Mar. 25	MT
Innocan Pharma Corporation Announces Tissue Distribution Study of LPT-CBD to the Brain	Mar. 05	CI
InnoCan Pharma Corporation Announces Study Findings That Lpt-Cbd Maintain Its Prolonged Release in Rabbits	Feb. 26	CI
InnoCan Pharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 29	CI
InnoCan Pharma Brief: Says "Surge" in revenue Primarily attributable to "Robust" sales performance of Subsidiary, B.I. Sky Global Ltd.	Nov. 29	MT
InnoCan Pharma Brief: Reporting US$4.083 Million In Revenues for Q3 2023 Vs US$749,000 for Q3 2022, representing an increase of 445%	Nov. 29	MT
Innocan Pharma Corporation Announces Promising LPT-CBD Safety Indications	Nov. 03	CI
Innocan Pharma Corporation Announces Promising Results from Hair Care Cream Efficacy Test	23-09-05	CI
Innocan Pharma Corporation Announces Clinical Study Results	23-08-28	CI
InnoCan Pharma Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights InnoCan Pharma Corporation Deutsche Boerse AG

Equities

IP4

CA45783P1027

Highlights

Filters